This page lists clinical trials for treating West Nile virus disease as a service to medical providers and the public and does not imply CDC endorsement of the entity conducting the study or the drug under investigation. The order of the studies below reflects the timing of their admission to the list only. To gain more information about any of these clinical trials, follow the website link associated with the study description.

Studies included on the list below must meet the following ethical and scientific criteria:

Institutional Review Board (IRB) approved
Randomized
Double-blinded
Placebo-controlled

The following studies have met these criteria:

1) A Phase I/II Randomized, Placebo-controlled Trial to Assess the Safety and Efficacy of Intravenous Immunoglobulin G (Omr-IgG-am) Containing High Anti-West Nile Virus Antibody Titers in Patients With, or at High Risk for Progression to West Nile Virus (WNV) Encephalitis and/or Myelitis. Sponsored by: National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health.
Contact: Walla Dempsey, Tel. (301) 496-7453, e-mail: wdempsey@niaid.nih.gov
Website: http://www.clinicaltrials.gov/show/NCT00068055

2) A Randomized Double-Blinded, Placebo Controlled Trial of Alpha-Interferon (Alferon) Therapy for West Nile Meningoencephalitis (Protocol WN-102).
Contact: James J. Rahal, MD, Tel. (718)-670-1525, email: JJR9002@nyp.org
Website: http://www.nyhq.org/posting/rahal.html

3) An Exploratory Study of the Safety, Tolerability, Pharmacokinetics and Potential Effectiveness of AVI-4020 Injection in Patients Presenting with Presumptive Acute Neuroinvasive West Nile Virus (WNV) Disease.
Contact: Desiree Hollemon, MSN, MPH, RN, Tel. (503) 227-0554, email: DHollemon@avibio.com
Website: http://www.clinicaltrials.gov/ct/show/NCT00091845

To submit information about additional clinical trials for possible inclusion on this page, please contact CDC's Division of Vector-Borne Infectious Diseases at (970) 221-6400.